Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Coveler AL, Smith DC, Phillips T, Curti BD, Goel S, Mehta AN, Kuzel TM, Markovic SN, Rixe O, Bajor DL, Gajewski TF, Gutierrez M, Lee HJ, Gopal AK, Caimi P, Heath EI, Thompson JA, Ansari S, Jacquemont C, Topletz-Erickson A, Zhou P, Schmitt MW, Grilley-Olson JE. Coveler AL, et al. Among authors: lee hj. J Immunother Cancer. 2023 Jun;11(6):e005584. doi: 10.1136/jitc-2022-005584. J Immunother Cancer. 2023. PMID: 37385724 Free PMC article. Clinical Trial.
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Gordon MJ, et al. Among authors: lee hj. Cancer. 2024 Mar 15;130(6):876-885. doi: 10.1002/cncr.35114. Epub 2023 Nov 20. Cancer. 2024. PMID: 37985359 Clinical Trial.
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.
Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Chihara D, et al. Among authors: lee hj. Cancer. 2016 Oct 15;122(20):3145-3151. doi: 10.1002/cncr.30173. Epub 2016 Jun 28. Cancer. 2016. PMID: 27351173 Free article.
Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.
Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Strati P, et al. Among authors: lee hj. Leuk Lymphoma. 2020 Jun;61(6):1380-1387. doi: 10.1080/10428194.2020.1716221. Epub 2020 Jan 23. Leuk Lymphoma. 2020. PMID: 31971032
Pembrolizumab for the treatment of Hodgkin Lymphoma.
Al Hadidi SA, Lee HJ. Al Hadidi SA, et al. Among authors: lee hj. Expert Opin Biol Ther. 2020 Nov;20(11):1275-1282. doi: 10.1080/14712598.2020.1830056. Epub 2020 Oct 16. Expert Opin Biol Ther. 2020. PMID: 33006479 Review.
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma.
Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Nastoupil LJ, et al. Among authors: lee hj. Leuk Lymphoma. 2021 Dec;62(14):3452-3462. doi: 10.1080/10428194.2021.1957874. Epub 2021 Aug 9. Leuk Lymphoma. 2021. PMID: 34365878 Clinical Trial.
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.
Steiner RE, Hwang SR, Khurana A, Habermann TM, Epperla N, Annunzio K, Allen PB, Baird K, Paulino D, Alderuccio JP, Lossos IS, David K, Evens AM, Pandya K, Bair SM, Kamdar M, Ba Aqeel S, Torka P, Lynch R, Smith S, Feng L, Noorani M, Ahmed S, Nair R, Vega F, Wu S, Fang P, Pinnix CC, Gunther JR, Dabaja BS, Lee HJ. Steiner RE, et al. Among authors: lee hj. Blood Adv. 2023 Dec 26;7(24):7485-7493. doi: 10.1182/bloodadvances.2023010700. Blood Adv. 2023. PMID: 37603594 Free PMC article.
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.
Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Lee HJ, et al. Oncologist. 2017 May;22(5):549-553. doi: 10.1634/theoncologist.2016-0328. Epub 2017 Apr 13. Oncologist. 2017. PMID: 28408615 Free PMC article. Clinical Trial.
13,116 results
You have reached the last available page of results. Please see the User Guide for more information.